Acorda Therapeutics (NASDAQ:ACOR) Stock Crosses Above 200 Day Moving Average of $0.63

Shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR – Get Rating) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.63 and traded as high as $0.95. Acorda Therapeutics shares last traded at $0.90, with a volume of 61,784 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Acorda Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, January 29th.

Acorda Therapeutics Stock Down 2.3 %

The company’s fifty day simple moving average is $0.86 and its 200-day simple moving average is $0.63. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.71 and a quick ratio of 1.34. The firm has a market capitalization of $21.94 million, a PE ratio of -0.13 and a beta of 1.43.

Hedge Funds Weigh In On Acorda Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Deutsche Bank AG purchased a new position in Acorda Therapeutics in the fourth quarter worth $26,000. Renaissance Technologies LLC grew its holdings in shares of Acorda Therapeutics by 1.5% during the fourth quarter. Renaissance Technologies LLC now owns 868,892 shares of the biopharmaceutical company’s stock valued at $666,000 after buying an additional 13,100 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Acorda Therapeutics by 44.8% during the fourth quarter. Geode Capital Management LLC now owns 67,669 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 20,948 shares during the last quarter. Prudential Financial Inc. purchased a new stake in shares of Acorda Therapeutics during the second quarter valued at $28,000. Finally, Millennium Management LLC grew its holdings in shares of Acorda Therapeutics by 661.2% during the second quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 270,588 shares during the last quarter. 25.86% of the stock is owned by hedge funds and other institutional investors.

Acorda Therapeutics Company Profile

(Get Rating)

Acorda Therapeutics, Inc engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm’s also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22.